Economic Impact of Neutropenia and Febrile Neutropenia in Breast Cancer: Estimates from Two National Databases
Authors:
- 1 June 2001
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 21 (6) , 684-690
Abstract
Study Objective. To estimate the economic burden of neutropenia and febrile neutropenia in female breast cancer hospital admissions in the United States. Design. Retrospective database analysis. Patients. Female admissions with a breast cancer diagnosis. Measurements and Main Results. By reviewing two national databases (Healthcare Costs and Utilization Project, MarketScan), length of stay and charge or payment/admission were estimated from 1994–1996. Neutropenic and febrile neutropenic admissions were longer and incurred higher charges and payments than nonneutropenic and afebrile neutropenic admissions, respectively (pConclusion. There was a trend toward decreased charges for inpatient admissions with neutropenia in patients with breast cancer (1994–1996). Interventions that reduce the frequency of neutropenia and febrile neutropenia could reduce hospitalization costs of breast cancer admissions.Keywords
This publication has 24 references indexed in Scilit:
- Chemotherapy dose reduction and delay in clinical practiceEuropean Journal of Cancer, 2000
- Outpatient antibiotic treatment in low-risk febrile neutropenic cancer patientsSupportive Care in Cancer, 1996
- FilgrastimPharmacoEconomics, 1996
- Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapyEuropean Journal of Cancer, 1995
- Improving Treatment of Chemotherapy-Induced Neutropenic Fever by Administration of Colony-Stimulating FactorsJNCI: Journal of the National Cancer Institute, 1995
- The Costs of Treating Febrile Neutropenia in Patients with Malignant Blood DisordersPharmacoEconomics, 1994
- Economic study of neutropenia induced by myelotoxic chemotherapyPharmacy World & Science, 1994
- The costs of treating febrile neutropenia in six U.K. HospitalsEuropean Journal of Cancer, 1993
- Recombinant Granulocyte Colony-Stimulating Factor (rG-CSF)PharmacoEconomics, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987